Oncopharmpod

Maya Leiva, PharmD, BCOP joins the Pod once again this Pride month to give us some LGBTQ clinical pearls on carboplatin dosing in trans patients and pregnancy/teratogenicity chemo counseling. LGBT Cancer Network: https://cancer-network.org

Highlights from ASCO's 2022 annual meeting.

Maya Leiva, PharmD, BCOP joins the Pod for Pride to give an overview of cancer screenings in the transgender population.

Looking at some interesting articles as possible predictors of what to expect next in NSCLC and AML. NADIM: https://pubmed.ncbi.nlm.nih.gov/?term=35576508 Ven + Intensive Chemo: https://doi.org/10.1016/S2352-3026(22)00100-4

By listener request, we discuss how to utilize our favorite guidelines.

A Foundation of OncoPharm: Docetaxel

The Landmarks of OncoPharm series returns to discuss 2 landmark studies (and 1 editorial) in head & neck cancer. Editorial: https://ascopubs.org/doi/pdf/10.1200/JCO.22.00274 EUORTC Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032641 Intergroup Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032646

The highlights, and only the highlights, of melanoma.

Treatment-free remission (TFR) rates in CML of close to 80% have recently been described (https://doi.org/10.1002/ajh.26550). The AGILE study. If you can't say anything nice. Checking back in on CHECKMATE 816 (neoadjuvant Nico-Chemo in NSCLC) and Keynote-177 (pembrolizumab in MSI-H/dMMR colorectal cancer).

Ribociclib-Tamoxifen: A Cautionary Tale by John Bossaer

Catching on recent FDA approvals on relatlimab/nivolumab (it's relatLimab not relatimab) as well as Lu-PSMA-177 based on the VISION trial.

Open up your Yelp app and check out Leukemia Pharmacist & Boston denizen Jessie Signorelli's recommendations for eating, drinking, & sight seeing in Boston. Also, great educational programming awaits!

Trastuzumab deruxtecan vs. trastuzumab trastuzumab

We look at two recent studies that illustrate a framework for how we identify risk factors and possible predictors of chemotherapy toxicity. Paclitaxel and skeletal muscle mass: https://doi.org/10.1111/bcp.15244 Sex differences of toxicity risk: https://doi.org/10.1200/jco.21.02377

Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.

The Landmarks of OncoPharm series returns to discuss the origins of "7 + 3" 7 + 3 > 5 + 2: https://doi.org/10.1182/blood.V58.6.1203.1203

We discuss the evolution of metastatic prostate cancer treatments leading up to last week's publication of ARASENS. Also, PROPEL and MAGNITUDE hint at an earlier role in therapy of PARP-inhibitors in prostate cancer. Maybe.

Foundations of OncoPharm: BCG and its fascinating history and role in non-muscle invasive bladder cancer. History of BCG: https://pubmed.ncbi.nlm.nih.gov/17997439/

This week we hype the seemingly negative impact of KIR2DS1/HLA-C2/C2 genotype on rituximab benefit in aggressive lymphomas. We also cover updates in breast cancer (pembrolizumab in TNBC; AIs in pre-menopausal women) and cervical cancer (cemiplimab). KIR & Rituximab: https://doi.org/10.1016/S2352-3026(21)00369-0 Keynote-522 Update w/ EFS analysis: https://www.nejm.org/doi/full/10.1056/NEJMoa2112651 Premenopausal Breast Cancer AIs vs. Tam Meta-Analysis: https://doi.org/10.1016/S1470-2045(21)00758-0 Cemiplimab in cervical cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2112187

We quickly cover some of the ASCO GI highlights from a couple weeks ago and delve deep into the role of ICIs in metastatic esophageal caner. Finally, does tebentafusp's approval tell us anything about the future intersection of immunotherapy and precision medicine?